Citius Pharmaceuticals, Inc. 8-K

What Happened Citius Pharmaceuticals, Inc. (CTXR) filed an 8-K reporting the results of its annual meeting of stockholders held on April 6, 2026. Stockholders re-elected seven directors to one-year terms expiring at the 2027 annual meeting: Leonard Mazur; Myron Holubiak; Suren Dutia; Dr. Eugene Holuka; Dennis M. McGrath; Robert Smith; and Carol Webb. The filing also reports that shareholders ratified the selection of Wolf & Company, P.C. as the company’s independent registered public accounting firm for the fiscal year ending September 30, 2026.

Key Details

• Director election vote totals (For / Withheld / Broker Non-Votes):
  • Leonard Mazur: 2,391,069 / 1,071,618 / 6,660,992
  • Myron Holubiak: 2,390,702 / 1,071,985 / 6,660,992
  • Suren Dutia: 2,311,462 / 1,151,225 / 6,660,992
  • Dr. Eugene Holuka: 2,391,419 / 1,071,268 / 6,660,992
  • Dennis M. McGrath: 2,449,029 / 1,013,658 / 6,660,992
  • Robert Smith: 2,485,904 / 976,783 / 6,660,992
  • Carol Webb: 2,422,082 / 1,040,605 / 6,660,992
• Auditor ratification vote: 8,593,946 for; 855,866 against; 673,867 abstaining; no broker non-votes.
• Each director was elected for a one-year term ending at the 2027 annual meeting or until a successor is qualified.

Why It Matters These results confirm the company’s board makeup and continuity of governance for the coming year, which can affect oversight of strategy and operations. Ratification of Wolf & Company as auditor establishes the firm responsible for auditing CTXR’s financial statements for the fiscal year ending September 30, 2026. No changes to executive officers or control were reported in this filing.